Tetratricopeptide repeat protein 39C (TTC39C)

Tetratricopeptide repeat protein 39C (TTC39C) is a cytoplasmic protein characterized by multiple tetratricopeptide repeat (TPR) domains, which are structural motifs facilitating protein-protein interactions[2][3]. While its precise function is incompletely defined, it is implicated in the regulation of protein complexes central to cell cycle progression, primarily anaphase, and signal transduction. TTC39C is widely expressed, with highest expression in the liver and substantial levels in various other tissues[3][7]. In skeletal muscle, TTC39C is required for proper differentiation and modulates signaling through MAP kinase and Hedgehog pathways[1][2]. It is upregulated during skeletal muscle atrophy and has been shown to be necessary for MAPK and Hedgehog signaling in muscle cells[1]. In cancer, especially lung adenocarcinoma, TTC39C is significantly upregulated, correlating with poor prognosis, enhanced cell proliferation, clonogenicity, and metastasis; suppression leads to reduced proliferation and increased apoptosis in vitro and in vivo[2]. Studies in zebrafish link its ortholog to ciliogenesis, left-right patterning, and organogenesis[5]. No approved drugs directly modulate TTC39C, nor are there known therapeutic mechanisms or safety liabilities reported in the literature as of now. **Key points:** - Canonical full name: Tetratricopeptide repeat protein 39C (TTC39C) - Considered a molecular scaffold protein with roles in protein complex assembly, cell signaling, and disease, especially in muscle biology and cancer[1][2][3]. - No direct therapeutic drugs or targeted therapies are established at present.

Other names

Tetratricopeptide repeat domain 39CTPR repeat protein 39CC18orf17FLJ33761HsT2697